Jazz drops PTSD drug over phase 2 trial failure

Jazz Pharmaceuticals is planning to drop its post-traumatic stress disorder (PTSD) therapy after the small molecule selective fatty acid amide hydrolase (FAAH) inhibitor failed to beat placebo in a phase 2 study.